The strong Q1 beat and reaffirmed guidance support the bullish thesis, but the CEO transition introduces near-term uncertainty. Watch for any strategic shifts under new leadership and monitor the Nelson Labs segment for stabilization. The stock may gap up on the beat, but the CEO change could cap upside.
Price Chart
Executive Summary
Sotera Health reported Q1 2026 Adjusted EPS of $0.18, a 29% YoY increase, and total net revenues of $280M (+10.0% YoY), both exceeding consensus estimates. The company reaffirmed its full-year 2026 outlook for 5.0%-6.5% constant currency revenue growth and 5.5%-7.0% Adjusted EBITDA growth, while also announcing a planned CEO transition. Strong performance at Sterigenics and Nordion drove the beat, partially offset by a slight decline at Nelson Labs.
Key Financial Metrics
Key Facts
- Q1 2026 Adjusted EPS of $0.18 vs consensus $0.17, a 5.9% beat
- Q1 2026 total net revenues of $280M, up 10.0% YoY, above consensus $270.8M
- Sterigenics segment revenue +9.7% YoY to $186M; Nordion +29.0% YoY to $42M
- Adjusted EBITDA of $134.7M, up 10.5% YoY; margin expanded to 48.1% from 47.9%
- Full-year 2026 outlook reaffirmed: net revenue $1.233B-$1.251B, Adjusted EBITDA $632M-$641M
- Net leverage ratio at 3.2x with over $900M in available liquidity
- Planned CEO transition announced in a separate release
Financial Impact
Q1 revenue beat by ~$9.2M (3.4%) vs consensus; EPS beat by $0.01 (5.9%)
Risk Factors
- CEO transition could signal strategic or operational changes
- Nelson Labs segment revenue declined 0.7% YoY, with segment income down 11.5%
- Ongoing EO litigation costs and professional fees remain a drag on earnings
- Net leverage at 3.2x limits financial flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287515 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | Institutional Cluster | $18.13 $18.10 | ▼ −0.17% | ▲ +0.36% | $18.49 (+1.99%) |
Oct 9, 2026 18d ago | SC 13G/A | $18.15 $18.21 | ▼ −0.33% | ▼ −0.34% | $18.49 (−1.87%) |
Aug 14, 2026 10w ago | 8-K | $18.89 $18.80 | ▼ −0.48% | ▼ −0.00% | $18.49 (−2.12%) |
Aug 9, 2026 11w ago | Institutional Cluster | $18.97 $19.11 | ▲ +0.74% | ▲ +1.06% | $18.49 (−2.53%) |
Aug 7, 2026 11w ago | 144 | $18.86 $18.97 | ▲ +0.58% | ▲ +0.61% | $18.49 (−1.96%) |
Aug 6, 2026 11w ago | 8-K | $18.91 $18.86 | ▼ −0.26% | ▼ −0.88% | $18.49 (−2.22%) |
May 27, 2026 21w ago | 3 | $15.75 $15.64 | ▼ −0.70% | ▼ −0.94% | $18.49 (+17.40%) |
May 20, 2026 22w ago | 8-K | $15.71 $15.66 | ▼ −0.32% | ▼ −0.76% | $18.49 (+17.70%) |
May 15, 2026 23w ago | Insider Cluster | $15.35 $15.23 | ▲ +0.78% | ▲ +0.13% | $18.49 (−20.46%) |
May 15, 2026 23w ago | Insider Cluster | $15.35 $15.23 | ▲ +0.78% | ▲ +0.13% | $18.49 (−20.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers